This Plain Language Summary of publication article (PLSP) from Future Oncology evaluates if zanidatamab, a research drug, could help people with HER2-amplified biliary tract cancer, a condition where cancer cells have extra copies of the HER2 gene. The phase 2b study included participants with advanced or metastatic cancer that had worsened after chemotherapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study’ that was published in The Lancet Oncology.

Visit The Lancet using the link to read the original article.